Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.

Tomohiko KimuraJunpei SanadaMasashi ShimodaHidenori HirukawaYoshiro FushimiMomoyo NishiokaTomoe KinoshitaSeizo OkauchiAtsushi ObataKenji KoharaFuminori TatsumiShinji KameiShuhei NakanishiTomoatsu MuneKohei KakuHideaki Kaneto

Published in: Journal of diabetes investigation (2017)

Switching from thiazide diuretic to an SGLT2 inhibitor, ipragliflozin, markedly improved various metabolic parameters and body mass composition without affecting blood pressure in participants with type 2 diabetes and hypertension.

Keyphrases

blood pressure
low dose
hypertensive patients
heart rate
high dose
blood glucose
adipose tissue
skeletal muscle